SUVEN · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 49/100 — Quality 33 · Momentum 88
| Share price | ₹338.50 |
| Market cap | ₹10,112 Cr |
| P/B ratio | 13.7 |
| ROCE | -46.5% |
| Book value | ₹26.20 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹7 Cr | ₹-276 Cr | -4,001.0% |
| 2025 | ₹7 Cr | ₹-161 Cr | -2,487.0% |
| 2024 | ₹12 Cr | ₹-105 Cr | -1,094.0% |
| 2023 | ₹14 Cr | ₹-118 Cr | -929.0% |
| 2022 | ₹12 Cr | ₹-122 Cr | -1,032.0% |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive